A team of researchers from Bose Institute in Kolkata has developed a peptide therapy that offers a promising, multidisciplinary approach to treating fungal keratitis -- a severe, sight-threatening infection of the cornea -- the clear front part of the eye. 

The team, including researchers from the L V Prasad Eye Institute in Hyderabad, designed a 15-residue peptide, named SA-XV, derived from a larger host-defense peptide -- S100A12. This peptide, previously shown to inhibit fungal growth, has been characterised for its antifungal potency and mechanism of action.